Your browser is no longer supported. Please, upgrade your browser.
NLS Pharmaceutics AG
Index- P/E- EPS (ttm)-0.55 Insider Own45.57% Shs Outstand11.07M Perf Week-10.08%
Market Cap13.15M Forward P/E- EPS next Y-0.29 Insider Trans0.00% Shs Float6.57M Perf Month-18.32%
Income-6.20M PEG- EPS next Q-0.54 Inst Own14.40% Short Float1.71% Perf Quarter-55.60%
Sales- P/S- EPS this Y47.50% Inst Trans- Short Ratio0.03 Perf Half Y-65.48%
Book/sh0.38 P/B2.82 EPS next Y46.30% ROA- Target Price10.00 Perf Year-
Cash/sh0.58 P/C1.85 EPS next 5Y- ROE- 52W Range1.02 - 7.35 Perf YTD-3.60%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-85.71% Beta-
Dividend %- Quick Ratio6.90 Sales past 5Y- Gross Margin- 52W Low2.94% ATR0.15
Employees2 Current Ratio6.90 Sales Q/Q- Oper. Margin- RSI (14)37.07 Volatility8.53% 13.80%
OptionableNo Debt/Eq0.00 EPS Q/Q-43.40% Profit Margin- Rel Volume0.10 Prev Close1.07
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume3.77M Price1.05
Recom2.00 SMA20-13.72% SMA50-30.47% SMA200-58.82% Volume31,067 Change-1.87%
Jan-12-22 08:15AM  
Jan-04-22 08:15AM  
Nov-30-21 08:30AM  
Nov-01-21 08:15AM  
Oct-20-21 08:48AM  
Oct-14-21 08:30AM  
Oct-04-21 04:30PM  
Sep-30-21 11:55AM  
Sep-28-21 08:30AM  
Sep-24-21 08:15AM  
Sep-14-21 08:30AM  
Sep-08-21 08:00AM  
Aug-19-21 11:44AM  
Aug-05-21 08:30AM  
Jul-30-21 09:08AM  
Jul-19-21 08:30AM  
Jul-15-21 08:15AM  
Jul-09-21 08:15AM  
Jul-08-21 11:20AM  
Jun-23-21 09:35AM  
Jun-15-21 06:41AM  
Jun-02-21 08:00AM  
May-28-21 08:15AM  
May-27-21 07:15PM  
May-18-21 01:29PM  
Apr-05-21 08:30AM  
Mar-29-21 08:30AM  
Mar-12-21 12:32PM  
Feb-25-21 09:00AM  
Feb-02-21 04:00PM  
Jan-28-21 07:30PM  
NLS Pharmaceutics AG, a biopharmaceutical company, engages in the discovery and development of drug therapies to treat rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience, for the treatment of excessive daytime sleepiness and cataplexy; and Nolazol, for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is based in Stans, Switzerland.